Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free APLMW Stock Alerts

Apollomics (APLMW) Competitors

Apollomics logo
$0.01 0.00 (-18.35%)
As of 11:59 AM Eastern
Compare

APLMW vs. SXTPW, DRTSW, BIVIW, CDIOW, and CELUW

Should you buy Apollomics stock or one of its competitors? MarketBeat compares Apollomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apollomics include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), BioVie (BIVIW), Cardio Diagnostics (CDIOW), and Celularity (CELUW). These companies are all part of the "biotechnology" industry.

How does Apollomics compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Apollomics (NASDAQ:APLMW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Apollomics had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat Apollomics' score of 0.43 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Apollomics Neutral

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Apollomics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats 60 Degrees Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does Apollomics compare to Alpha Tau Medical?

Apollomics (NASDAQ:APLMW) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Alpha Tau MedicalN/AN/AN/AN/AN/A

In the previous week, Apollomics had 1 more articles in the media than Alpha Tau Medical. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 1.89 beat Apollomics' score of 0.43 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
Alpha Tau Medical Very Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Alpha Tau Medical N/A N/A N/A

Summary

Apollomics beats Alpha Tau Medical on 2 of the 3 factors compared between the two stocks.

How does Apollomics compare to BioVie?

BioVie (NASDAQ:BIVIW) and Apollomics (NASDAQ:APLMW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, Apollomics had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for BioVie. BioVie's average media sentiment score of 1.89 beat Apollomics' score of 0.43 indicating that BioVie is being referred to more favorably in the media.

Company Overall Sentiment
BioVie Very Positive
Apollomics Neutral

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Apollomics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Apollomics$8.50MN/AN/AN/AN/A

Summary

Apollomics beats BioVie on 2 of the 3 factors compared between the two stocks.

How does Apollomics compare to Cardio Diagnostics?

Apollomics (NASDAQ:APLMW) and Cardio Diagnostics (NASDAQ:CDIOW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

In the previous week, Apollomics had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 1.89 beat Apollomics' score of 0.43 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
Cardio Diagnostics Very Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Cardio Diagnostics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Cardio Diagnostics$16.57KN/AN/AN/AN/A

Summary

Apollomics beats Cardio Diagnostics on 2 of the 3 factors compared between the two stocks.

How does Apollomics compare to Celularity?

Apollomics (NASDAQ:APLMW) and Celularity (NASDAQ:CELUW) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Celularity had 1 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for Celularity and 2 mentions for Apollomics. Celularity's average media sentiment score of 0.75 beat Apollomics' score of 0.43 indicating that Celularity is being referred to more favorably in the news media.

Company Overall Sentiment
Apollomics Neutral
Celularity Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Celularity N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Celularity$26.55MN/AN/AN/AN/A

Summary

Celularity beats Apollomics on 3 of the 3 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLMW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLMW vs. The Competition

Export
MetricApollomicsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$454.79M$6.50B$12.37B
Dividend YieldN/A3.88%2.67%5.66%
P/E RatioN/A3.1724.0124.71
Price / SalesN/A6,488.68540.55165.59
Price / CashN/A13.1327.4837.92
Price / BookN/A88.0210.556.85
Net IncomeN/A-$96.07M$3.56B$337.45M
7 Day PerformanceN/A0.64%1.54%2.70%
1 Month PerformanceN/A0.38%2.48%4.60%
1 Year PerformanceN/A58.74%26.49%32.81%

Apollomics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLMW
Apollomics
N/A$0.01
-18.4%		N/A-9.7%$0.00$8.50MN/A59
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
+0.3%		N/AN/A$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$2.00
flat		N/A+773.3%$0.00N/AN/A80
BIVIW
BioVie
N/A$0.30
+20.3%		N/AN/A$0.00N/AN/AN/A
CDIOW
Cardio Diagnostics
N/A$0.02
+33.3%		N/A+23.3%$0.00$16.57KN/A7

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:APLMW) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel